Multiple modalities of TSC2 alterations, including loss of heterozygosity (LOH), somatic mutations, rearrangements, and deletions [8–12], have been detected in S-LAM patients [8, 9, 13, 14]. This evidence concerns the gene TSC2 and lymphangioleiomyomatosis.